Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 June 2018 Photo Prof CB Bousman, from Texas State University.
Quaternary International volume dedicated to UFS research fellow
Dr James Brink visits the Erfkroon site on the Modder River in the Free State.

The contents of a special issue of Quaternary International (QI), consisting of 13 articles and contributions by 45 authors (25 from abroad), was recently presented to Dr James Simpson Brink. The papers represent the broad range of topics covered by Dr Brink’s research interests.  

The special issue of QI was initiated to coincide with James Simpson Brink’s 60th birthday after he recently celebrated 35 years of ground-breaking research at the National Museum of Bloemfontein.

Dr Brink is affiliated to the Centre for Environmental Management at the University of the Free State (UFS).

Prof Louis Scott, researcher in the Department of Plant Sciences at the UFS, was the executive guest editor, and was part of a team of three guest editors (Dr Liora Horwitz from the Hebrew University in Jerusalem, and Dr Daryl Codron from the National Museum in Bloemfontein) who worked on this special issue of the journal, QI. 

In honour of a friend and colleague
“Dr Brink made contributions to osteology, Quaternary palaeontology, and archaeozoology, by investigating the environments and mechanisms that drove the evolution of mammal communities of southern Africa,” said the guest editors. 

“By studying the morphology of the endemic black wildebeest he demonstrated how the species evolved in the central interior of South Africa. He pioneered descriptions and dating of faunal assemblages that make up the so-called ‘Cornelian’ and ‘Florisian’ Land Mammal Ages. In this way he reconstructed the long history of environments in which Stone Age occupants survived in the region. The work included the age determination of the cranium with facial bones of an individual who lived at Floribad around 250 000 years ago.

Work enabled more important studies
“Dr Brink contributed more than purely academic insights in that he built and curated the modern mammal and fossil faunal collections of the Florisbad Quaternary Research Station. These collections made it possible for researchers, who came from all over the world, to visit the Free State and focus on spatial and temporal palaeoenvironmental trends. Apart from contributing to the functional diversity of mammalian species, this enabled the investigation of morphological and behavioural variations across populations and communities,” said the editors.

The topics of the papers in this special issue of QI are interdisciplinary and include different methods in archaeology, vertebrate palaeontology and past (or palaeo-) environmental reconstruction. The ages dealt with range from the relatively recent Iron Age to the Oldowan period, which is over a million years old.

According to Prof Scott, with a degree of overlap in the interdisciplinary fields studied, the papers can be arranged into 1) taphonomy and archaeozoology, relating to the processes resulting in the formation and preservation of fossil material in archaeological sites, 2) Stone Age archaeology, dealing with artefacts, stratigraphy and palaeoanthropology, and 3) palaeoecology, that includes palaeontology, isotope studies and palaeoenvironmental reconstructions.

The journal, published by Elsevier, will be distributed worldwide. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept